Navigation Links
Clinical trial shows tongue-controlled wheelchair outperforms popular wheelchair navigation system
Date:11/27/2013

g and the National Science Foundation funded the research. Scientists from Shepherd Center in Atlanta, and the Rehabilitation Institute of Chicago and the Northwestern University Feinberg School of Medicine in Chicago were also involved in the study.

"The Tongue Drive System is a novel technology that empowers people with disability to achieve maximum independence at home and in the community by enabling them to drive a power wheelchair and control their environment in a smoother and more intuitive way," said Northwestern co-lead investigator Elliot Roth, M.D, chair of physical medicine and rehabilitation at Feinberg and the medical director of the patient recovery unit at Rehabilitation Institute of Chicago. "The opportunity to use this high-tech innovation to improve the quality of life among people with mobility limitations is very exciting."

The research team had subjects complete a set of tasks commonly used in similar clinical trials. Subjects in the trials were either able-bodied or people with tetraplegia.

"By the end of the trials, everybody preferred the Tongue Drive System over their current assistive technology," said Joy Bruce, manager of Shepherd Center's Spinal Cord Injury Lab and co-author of the study. "It allows them to engage their environment in a way that is otherwise not possible for them."

Researchers compared how able-bodied subjects were able to execute commands either with the Tongue Drive System or with a keypad and mouse. For example, targets randomly appeared on a computer screen and the subjects had to move the cursor to click on the target. Scientists are able to calculate how much information is transferred from a person's brain to the computer as they perform a point-and-click task. The performance gap narrowed throughout the trial between the keypad and mouse and the Tongue Drive System.

For the first time, the research team showed that people with tetraplegia can maneuver a wheelchair b
'/>"/>

Contact: Brett Israel
brett.israel@comm.gatech.edu
404-385-1933
Georgia Institute of Technology
Source:Eurekalert  

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. DermTechs Non-invasive Melanoma Detection Assay Poised to Enter Clinical Validation Study
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
6. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
7. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
8. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
9. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Clinical trial shows tongue-controlled wheelchair outperforms popular wheelchair navigation system
(Date:3/31/2015)...  Bayer HealthCare (Bayer) has expanded its collaboration ... Technology (MIT) and Harvard University to include cardiovascular ... new part of the alliance is to leverage ... cardiovascular therapies. "We are excited to ... the area of cardiovascular genomics to discover genes ...
(Date:3/31/2015)... March 31, 2015 This June 13th, ... the top U.S and International Medical Schools will come ... research on the application of stem cell therapy in ... is organized and funded by the Ocular Research ... has been convening intimate meetings of top experts in ...
(Date:3/30/2015)... NC (PRWEB) March 30, 2015 ... are pleased to announce the formation of VaxCorps, ... research centers specializing in the conduct of vaccine ... VaxCorps clinical sites have successfully conducted over ... experience in seasonal and pandemic influenza as well ...
(Date:3/30/2015)... , March 30, 2015 US-Australian drug ... and its subsidiary, CanTx, Inc., and Yale University, on ... Cantrixil. The data was presented as an oral presentation ... Yale Medical School to the 62 nd Annual ... San Francisco, CA. ...
Breaking Biology Technology:Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2PMG Research announces formation of VaxCorps with two industry-leading vaccine site networks 2Yale University and Novogen Release Data on Cantrixil Mode of Action 2Yale University and Novogen Release Data on Cantrixil Mode of Action 3Yale University and Novogen Release Data on Cantrixil Mode of Action 4
... (NYSE: SGP ) will provide a live ... chairman and chief executive officer, followed,by a question-and-answer ... on Jan. 3, 2008, at approximately 8:45 a.m. ... presentation., Included in Mr. Hassan,s comments will ...
... Fla., Dec. 27 Phlo Corporation,(Pink Sheets: PHLC) ("Phlo") ... completed the initial shipment of its vitality beverage,product, AQISS(TM), ... in the,metropolitan New York City area, including Manhattan, Brooklyn, ... launched in a key account base, some of which ...
... Dec. 27 /Xinhua-PRNewswire/ -- Asymchem, one of China,s,leading ... plans in China. Apart from new plants and ... heavily in training and form strategic alliances,in the ... I. Quality Facilities: New cGMP Pilot Plant ...
Cached Biology Technology:Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference 2Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base 2Three Steps to Boost Asymchem's Investment in China 2Three Steps to Boost Asymchem's Investment in China 3Three Steps to Boost Asymchem's Investment in China 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/19/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... week on Washington DC,s Fox 5 ... "The Next Great Thing", host Laura Evans calls ... ,a really big breakthrough in mobile payment.,  ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3
... , BIRMINGHAM, Ala. A new study at the University ... and abdominal obesity, which has been linked to an increased ... that in a sample of young adults during a 15-year ... gained weight at a faster rate than others in the ...
... -- CoLucid Pharmaceuticals, Inc., ("CoLucid"), an innovative biotechnology ... disorders, today announced that its investigational first-in-class Neurally ... COL-144), a selective 5-HT1F receptor agonist, was effective ... as documented in a Phase IIb study. Results ...
... the 2010 International Conference on Emerging Infectious Diseases (ICEID), ... Regency, Atlanta, Georgia. The meeting is being organized ... the American Society for Microbiology, the Council of State ... and the World Health Organization. The International Conference ...
Cached Biology News:UAB study confirms link between depression, abdominal obesity 2CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks 22010 International Conference on Emerging Infectious Diseases 2
Mouse monoclonal [7E10] to C Peptide ( Abpromise for all tested applications). entrezGeneID: 3630 SwissProtID: P01308...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
...
Biology Products: